TY - JOUR
T1 - Clinical drug development using dynamic biomarkers to enable personalized health care in Chronic Obstructive Pulmonary Disease
AU - Bihlet, Asger R
AU - Karsdal, Morten A
AU - Bay-Jensen, Anne-Christine
AU - Read, Simon
AU - Kristensen, Jacob Hull
AU - Sand, Jannie Marie Bülow
AU - Leeming, Diana Julie
AU - Andersen, Jeppe Ragnar
AU - Lange, Peter
AU - Vestbo, Jørgen
PY - 2015/7
Y1 - 2015/7
N2 - Despite massive investments in development of novel treatments for heterogeneous diseases such as Chronic Obstructive Pulmonary Disease (COPD), the resources spent have only benefitted a fraction of the population treated. Personalized Health Care to guide selection of a suitable patient population already in the clinical development of new compounds could offer a solution. In this review, we discuss past successes and failures in drug development and biomarker research in COPD. We describe research in COPD phenotypes, and the required characteristics of a suitable biomarker for identifying patients at higher risk of progression. We review the role of extra-cellular matrix proteins found to be upregulated in COPD. Novel biomarkers of connective tissue remodeling which may provide added value for a personalized approach by detecting subgroups of patients with active disease suitable for pharmacological intervention are discussed.
AB - Despite massive investments in development of novel treatments for heterogeneous diseases such as Chronic Obstructive Pulmonary Disease (COPD), the resources spent have only benefitted a fraction of the population treated. Personalized Health Care to guide selection of a suitable patient population already in the clinical development of new compounds could offer a solution. In this review, we discuss past successes and failures in drug development and biomarker research in COPD. We describe research in COPD phenotypes, and the required characteristics of a suitable biomarker for identifying patients at higher risk of progression. We review the role of extra-cellular matrix proteins found to be upregulated in COPD. Novel biomarkers of connective tissue remodeling which may provide added value for a personalized approach by detecting subgroups of patients with active disease suitable for pharmacological intervention are discussed.
U2 - 10.1378/chest.15-0296
DO - 10.1378/chest.15-0296
M3 - Review
C2 - 25856563
SN - 0012-3692
VL - 148
SP - 16
EP - 23
JO - Chest
JF - Chest
IS - 1
ER -